Therapeutic insights: Use of ceftazidime-avibactam in pediatric patients.

Özge Metin Akcan Mustafa GençeliTalha ÜstüntaşAbdullah AkkuşSevgi PekcanMetin Doğan

Published in: Pediatrics international : official journal of the Japan Pediatric Society (2024)

Ceftazidime-avibactam may be a promising new drug option for the treatment of life-threatening infections caused by MDR Gram-negative microorganisms in pediatric patients. However, further studies with larger case series are needed to further evaluate the efficacy and safety of CAZ-AVI in this population.

Keyphrases

gram negative
multidrug resistant
klebsiella pneumoniae
emergency department
escherichia coli
combination therapy
replacement therapy
drug induced